150 related articles for article (PubMed ID: 23942221)
21. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
Ramzi S; Najeeb E; Coulthard J; Jenkins S
Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
[TBL] [Abstract][Full Text] [Related]
22. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
23. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
Eur J Cancer; 2017 Dec; 87():1-9. PubMed ID: 29096155
[TBL] [Abstract][Full Text] [Related]
24. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
[TBL] [Abstract][Full Text] [Related]
25. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
[TBL] [Abstract][Full Text] [Related]
27. Probability of axillary lymph node metastasis when sentinel lymph node biopsy is negative in women with clinically node negative breast cancer: a Bayesian approach.
Okamoto T; Yamazaki K; Kanbe M; Kodama H; Omi Y; Kawamata A; Suzuki R; Igari Y; Tanaka R; Iihara M; Ito Y; Sawada T; Nishikawa T; Maki M; Kusakabe K; Mitsuhashi N; Obara T
Breast Cancer; 2005; 12(3):203-10. PubMed ID: 16110290
[TBL] [Abstract][Full Text] [Related]
28. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
29. Rural and urban disparities in the evolution of sentinel lymph node utilization in breast cancer.
Arrington AK; Kruper L; Vito C; Yim J; Kim J; Chen SL
Am J Surg; 2013 Nov; 206(5):674-81. PubMed ID: 24035212
[TBL] [Abstract][Full Text] [Related]
30. Axillary Lymph Node Burden in Invasive Breast Cancer: A Comparison of the Predictive Value of Ultrasound-Guided Needle Biopsy and Sentinel Lymph Node Biopsy.
Boone BA; Huynh C; Spangler ML; Sumkin J; Johnson R; McGuire KP; Soran A; Ahrendt GM
Clin Breast Cancer; 2015 Oct; 15(5):e243-8. PubMed ID: 25922244
[TBL] [Abstract][Full Text] [Related]
31. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
Shin YD; Lee HM; Choi YJ
BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
[TBL] [Abstract][Full Text] [Related]
32. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
[TBL] [Abstract][Full Text] [Related]
33. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
[TBL] [Abstract][Full Text] [Related]
34. Adjusted Hospital Sentinel Lymph Node Positivity Rates in Melanoma: A Novel Potential Measure of Quality.
Kinnier CV; Paruch JL; Dahlke AR; Wayne JD; Benson AB; Winchester DP; Bilimoria KY
Ann Surg; 2016 Feb; 263(2):392-8. PubMed ID: 26488806
[TBL] [Abstract][Full Text] [Related]
35. Understanding age and race disparities in the application of sentinel lymph node biopsy in breast cancer.
Radhakrishnan A; Silverman P; Pollack CE; Pfoh ER; Shenk R; Thompson CL
J Investig Med; 2016 Dec; 64(8):1241-1245. PubMed ID: 27466395
[TBL] [Abstract][Full Text] [Related]
36. Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer.
Gui GP; Joubert DJ; Reichert R; Ward A; Lakhani S; Osin P; Nerurkar A; A'Hern R; Benson K; Underwood SR
Eur J Surg Oncol; 2005 Sep; 31(7):707-14. PubMed ID: 15993028
[TBL] [Abstract][Full Text] [Related]
37. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society.
Park HS; Chae BJ; Song BJ; Jung SS; Han W; Nam SJ; Youn HJ; Ko BK; Kim DW;
Ann Surg Oncol; 2014 Apr; 21(4):1231-6. PubMed ID: 24318094
[TBL] [Abstract][Full Text] [Related]
38. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging.
Vanderveen KA; Schneider PD; Khatri VP; Goodnight JE; Bold RJ
Ann Surg Oncol; 2006 Nov; 13(11):1450-6. PubMed ID: 17009150
[TBL] [Abstract][Full Text] [Related]
39. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update.
Schwartz GF
Breast J; 2004; 10(2):85-8. PubMed ID: 15009032
[TBL] [Abstract][Full Text] [Related]
40. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
